These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31586503)

  • 1. Lipoprotein(a) - Link between Atherogenesis and Thrombosis.
    Labudovic D; Kostovska I; Tosheska Trajkovska K; Cekovska S; Brezovska Kavrakova J; Topuzovska S
    Prague Med Rep; 2019; 120(2-3):39-51. PubMed ID: 31586503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a): Cellular Effects and Molecular Mechanisms.
    Riches K; Porter KE
    Cholesterol; 2012; 2012():923289. PubMed ID: 22991657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipoprotein(a): a link between thrombogenesis and atherogenesis].
    Vucković B; Derić M
    Med Pregl; 2007; 60(1-2):37-41. PubMed ID: 17853709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lipoprotein(a) in atherogenesis and thrombosis.
    Hajjar KA; Nachman RL
    Annu Rev Med; 1996; 47():423-42. PubMed ID: 8712793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipoprotein(a): a link between thrombosis and atherosclerosis?].
    Hansen PR
    Ugeskr Laeger; 1993 May; 155(20):1527-30. PubMed ID: 8316983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
    Schreml J; Gouni-Berthold I
    Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
    Tsimikas S; Hall JL
    J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?].
    de Brouckère V; Liénart F; Ducobu J
    Rev Med Brux; 2010; 31(3):171-6. PubMed ID: 20687444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) catabolism: a case of multiple receptors.
    McCormick SPA; Schneider WJ
    Pathology; 2019 Feb; 51(2):155-164. PubMed ID: 30595508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
    Boffa MB; Marcovina SM; Koschinsky ML
    Clin Biochem; 2004 May; 37(5):333-43. PubMed ID: 15087247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk.
    Discepolo W; Wun T; Berglund L
    Pathophysiol Haemost Thromb; 2006; 35(3-4):314-21. PubMed ID: 16877880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
    Ma L; Waldmann E; Ooi EMM; Chan DC; Barrett HPR; Watts GF; Parhofer KG
    Eur J Clin Invest; 2019 Feb; 49(2):e13053. PubMed ID: 30447089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ; Pottle A; Pennell DJ; Barbir MS
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
    Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
    Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.
    Reyes-Soffer G; Westerterp M
    Pharmacol Res; 2021 Jul; 169():105689. PubMed ID: 34033878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) and atherosclerosis.
    Scanu AM; Lawn RM; Berg K
    Ann Intern Med; 1991 Aug; 115(3):209-18. PubMed ID: 1829339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lp(a): a link between thrombosis and atherosclerosis.
    Scanu AM
    Eur J Epidemiol; 1992 May; 8 Suppl 1():76-8. PubMed ID: 1387094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.